036480 — Daesung Microbiological Labs Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapSucker Stock

Market Cap
KR₩41bn
Enterprise Value
KR₩53bn
Revenue
KR₩26bn

Annual income statement for Daesung Microbiological Labs Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	25,134	24,801	23,997	25,500	25,562
Cost of Revenue
Gross Profit	8,443	8,041	5,738	4,794	4,849
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	21,754	22,883	23,660	25,828	26,251
Operating Profit	3,380	1,918	337	-328	-689
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,813	1,529	843	2,261	-1,082
Provision for Income Taxes
Net Income After Taxes	2,471	1,519	866	1,703	-680
Net Income Before Extraordinary Items
Net Income	2,471	1,519	866	1,703	-680
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,471	1,519	866	1,703	-680
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	648	468	227	8.24	-179
Dividends per Share